Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:18 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard response Clear all
Recruiting Phase 2 Interventional

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

NCT06910124
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Linvoseltamab, Lenalidomide
Biological · Drug
Lead sponsor
Dickran Kazandjian, MD
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Completed Phase 1 Interventional

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

NCT03467373
View directory record Official record
Conditions
B-Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Nov 3, 2026, 2:18 AM EST
Withdrawn Phase 2 Interventional

Vedolizumab Post Op Study

NCT02834754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, placebo
Drug
Lead sponsor
Marc Schwartz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Nov 3, 2026, 2:18 AM EST
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Nov 3, 2026, 2:18 AM EST
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Nov 3, 2026, 2:18 AM EST
Recruiting No phase listed Observational

Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

NCT06550050
View directory record Official record
Conditions
Oral Cancer
Interventions
Radiation
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2066
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Recruiting Phase 3 Interventional

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330
View directory record Official record
Conditions
Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions
Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
154
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

CV Imaging of Metabolic Interventions

NCT05650307
View directory record Official record
Conditions
Bariatric Surgery Candidate, Heart Failure, Cardiovascular Diseases
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Terminated Phase 2 Interventional

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

NCT06568692
View directory record Official record
Conditions
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
PCS6422 and capecitabine, Capecitabine
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Oxnard, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Terminated Phase 2 Interventional Results available

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT02899728
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Carboplatin, Cediranib, Cediranib Maleate, Cisplatin, Etoposide, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Pasadena, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Nov 3, 2026, 2:18 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2

NCT06999265
View directory record Official record
Conditions
Female Sexual Dysfunction, Female Sexual Dysfunction Due to Physical Condition
Interventions
Transcutaneous electrical nerve stimulation - Tibial Nerve, Transcutaneous electrical nerve stimulation - Genital Nerve, Neutral and Erotic Film Clip Alternation
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 3, 2026, 2:18 AM EST
Completed Phase 1Phase 2 Interventional Results available

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

NCT03847519
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
Interventions
ADXS-503, Pembrolizumab
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Nov 3, 2026, 2:18 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers

NCT07656545
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Burns, Traumatic Injury, Acute Stress Disorder, Trauma and Stressor Related Disorders, Trauma and Stress Related Disorders, Stress Disorder, Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Relationship, Social
Interventions
Promotion of Emotional Disclosure for Burns (PoED-B), minimally Enhanced Usual Care control (mEUC)
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Recruiting Not applicable Interventional

Mechanistic Clinical Trial of Advanced Imaging for CRT

NCT03398369
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
CMR/CTA Guidance for CRT
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
20 Years to 90 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Nov 3, 2026, 2:18 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Mechanisms of Post-Bariatric Hypoglycemia

NCT04428866
View directory record Official record
Conditions
Hypoglycemia
Interventions
Continuous Glucose Monitoring, activity monitor, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome
Diagnostic Test
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Nov 3, 2026, 2:18 AM EST
Terminated Phase 3 Interventional Results available

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

NCT01467479
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Nov 3, 2026, 2:18 AM EST
Recruiting Phase 2 Interventional

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

NCT06794229
View directory record Official record
Conditions
Locally Advanced Renal Cell Carcinoma
Interventions
Zanzalintinib, Nivolumab
Drug
Lead sponsor
Qian Qin
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 3, 2026, 2:18 AM EST
Completed No phase listed Observational

Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI

NCT03656250
View directory record Official record
Conditions
Nasopharyngeal Cancer
Interventions
PET/CT scans
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Nov 3, 2026, 2:18 AM EST
Terminated Phase 2 Interventional Results available

Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

NCT00765570
View directory record Official record
Conditions
Advanced Bulky Malignancies
Interventions
Spatially Fractioned Radiation Therapy, Treatment Group 1, Standard radiation
Radiation
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Nov 3, 2026, 2:18 AM EST
Terminated Not applicable Interventional

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

NCT01052766
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
PET/CT and BH PET/CT
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Nov 3, 2026, 2:18 AM EST
Completed Phase 4 Interventional Results available

Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources

NCT01342523
View directory record Official record
Conditions
Smoking Cessation, Smoking, Nicotine Dependence
Interventions
CIS - telephone cessation quitline counseling, Lozenge - nicotine mini-lozenges, Emails - Brief smoking prevention messages, Full website - standard smokefree.gov website content, Lite website - lite version of smokefree.gov, Full mailed booklet - NCI's detailed 36-page quit guide, brief mailed booklet - smaller version of NCI's booklet
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Nov 3, 2026, 2:18 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pattern - Reach Aim 2

NCT04216264
View directory record Official record
Conditions
Obesity
Interventions
Standard response, Targeted response
Behavioral
Lead sponsor
Duke University
Other
Eligibility
2 Weeks to 2 Months
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Nov 3, 2026, 2:18 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Does Overpractice Improve Motor Learning?

NCT02898701
View directory record Official record
Conditions
Aging
Interventions
Motor Practice of a Standing Serial Reaction Time Task
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 95 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Nov 3, 2026, 2:18 AM EST